Polymer Hydrogels For In Vivo Applications And Methods For Using And Preparing Same

ABSTRACT

Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.

RELATED APPLICATIONS

This application claims, under 35 U.S.C. §119(e), the benefit of U.S.Provisional Patent Application Ser. No. 61/453,818, filed 17 Mar. 2011,the entire contents and substance of which are hereby incorporated byreference as if fully set forth below.

TECHNICAL FIELD

The various embodiments of the present disclosure relate generally topolymer hydrogel compositions, methods of making polymer hydrogelcompositions, and methods of using polymer hydrogel compositions. Moreparticularly, various embodiments of the present disclosure are directedtoward polymer hydrogels for in vivo delivery of biologically activematerials in therapeutic treatments.

BACKGROUND OF THE INVENTION

The controlled release of a therapeutic agent is a central premise ofmedicine. The controlled release over time of a pharmaceutical drug is arecognized, if not completely predictable, technology that is availablein numerous drugs currently on the market. While, controlled releaseoften indicates the release of a compound over a period of time, e.g.the time release of a chemical compound, controlled release can alsoindicate the release of a compound at a specific location, e.g. drugdelivery. Coated stent technology is an example of the delivery of adrug to the arterial area near the stent.

However, in contrast to the time release of simple chemical compounds ordelivery of a drug in from a stent, the controlled release ofrecombinant proteins in vivo via injectable delivery vehicles remains acentral challenge in drug delivery. PLGA-based injectable deliveryvehicles for model proteins and peptides have been developed, but thesedelivery vehicles have not been able to deliver recombinant proteinsbecause of their scarcity and fragility. As medicine continues todevelop recombinant proteins for therapeutic uses, there will remain aneed for delivery of those compounds.

Injectable hydrogels have been considered as a method for deliveringdrugs to a biological system. Hydrogels are composed of mutuallyreactive precursors that react in situ to form networks with high watercontent, mimicking mechanical and chemical properties of surroundingtissues. By varying the concentrations and chemical properties of thesoluble precursors, mesh size, degradation times, mechanical propertiesand release rates of therapeutic agents might be controlled. Althoughvarious materials have been used to form synthetic injectable hydrogels,by far the most widely studied gels are those formed from macromolecularpoly(ethylene glycol) (PEG) precursors. Numerous free radicalpolymerization mechanisms have been employed to generate hydrogelnetworks from soluble PEG-based precursors, but the initiators and freeradicals produced during polymerization have the potential to damage theencapsulated therapeutic agents and surrounding tissues. Thus thereremains a need to develop injectable hydrogels that are compatible within vivo uses.

SUMMARY

Various embodiments of the present invention are directed compositionsand uses of polymer hydrogels and the delivery of therapeutic agents invivo. More particularly, various embodiments of the present disclosureare directed to a polymer hydrogel, which can include a polyacrylatebackbone and a crosslinking member, methods of using the polymerhydrogel, methods of preparing the polymer hydrogel, and kits for thepolymer hydrogel.

In an embodiment of the present invention, the polymer hydrogel can be acompound of Formula I.

where R¹ and R² can each be independently hydrogen or a C₁ to C₆hydrocarbon; R³ can be hydrogen or methyl; X can be —O, —S— or —NR⁵—; Zis —OR⁶, —SR⁶, or NR⁵R⁶; m can greater than or equal to 1; x can be aninteger greater than zero and z can be zero or an integer greater thanzero; R⁵ can be hydrogen or C₁ to C₆ hydrocarbon; R⁶ can be hydrogen, C₁to C₆ hydrocarbon or a polyglycol chain of two to ten glycol units; eachR¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′), R^(12′), and R^(13′) canindependently be hydrogen, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, nitro,fluoro, chloro, or bromo; Y¹ and Y² can each independently be —O—, —S—,or —NR⁴— wherein R⁴ can be hydrogen or a C₁ to C₆ hydrocarbon; and L cancontain a polyglycol.

In an exemplary embodiment of the present invention, the polymerhydrogel can include a polyacrylate backbone of Formula II,

and a crosslinking member of Formula III

where R¹ and R² can each be independently hydrogen or a C₁ to C₆hydrocarbon; R³ can be hydrogen or methyl; X can be —O, —S— or —NR⁵—; Zis —OR⁶, —SR⁶, or NR⁵R⁶; m can greater than or equal to 1; x can be aninteger greater than zero and z can be zero or an integer greater thanzero; R⁵ can be hydrogen or C₁ to C₆ hydrocarbon; R⁶ can be hydrogen, C₁to C₆ hydrocarbon or a polyglycol chain of two to ten glycol units; eachR¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′), R^(12′), and R^(13′) canindependently be hydrogen, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, nitro,fluoro, chloro, or bromo; Y¹ and Y² can each independently be —O—, —S—,or —NR⁴— wherein R⁴ can be hydrogen or a C₁ to C₆ hydrocarbon; and L cancontain a polyglycol.

In an exemplary embodiment of the present invention, the polymerhydrogel can be prepared by the reaction of a polyacrylate azide ofFormula IV

with a crosslinking alkyne of Formula V

where R¹ and R² can each be independently hydrogen or a C₁ to C₆hydrocarbon; R³ can be hydrogen or methyl; X can be —O, —S— or —NR⁵—; Zis —OR⁶, —SR⁶, or NR⁵R⁶; m can greater than or equal to 1; x can be aninteger greater than zero and z can be zero or an integer greater thanzero; R⁵ can be hydrogen or C₁ to C₆ hydrocarbon; R⁶ can be hydrogen, C₁to C₆ hydrocarbon or a polyglycol chain of two to ten glycol units; eachR¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′), R^(12′), and R^(13′) canindependently be hydrogen, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, nitro,fluoro, chloro, or bromo; Y¹ and Y² can each independently be —O—, —S—,or —NR⁴— wherein R⁴ can be hydrogen or a C₁ to C₆ hydrocarbon; and L cancontain a polyglycol.

In an exemplary embodiment of the present invention, a kit for thetreatment of an anatomical part of a body can include an aqueoussolution of a polyacrylate azide of Formula IV, an aqueous solution of acrosslinking alkyne of Formula V, and an aqueous solution of atherapeutic agent. In a preferred embodiment, the anatomical part can bea bone.

In an exemplary embodiment of the present invention, a method fortreating a condition on or near a bone can be administering to a site onor near the bone a therapeutic agent in a polymer hydrogel of Formula Ior Formula VI

where R¹ and R² can each be independently hydrogen or a C₁ to C₆hydrocarbon; R³ can be hydrogen or methyl; X can be —O, —S— or —NR⁵—; Zis —OR⁶, —SR⁶, or NR⁵R⁶; m can greater than or equal to 1; x can be aninteger greater than zero and z can be zero or an integer greater thanzero; R⁵ can be hydrogen or C₁ to C₆ hydrocarbon; R⁶ can be hydrogen, C₁to C₆ hydrocarbon or a polyglycol chain of two to ten glycol units; Y¹and Y² can each independently be —O—, —S—, or —NR⁴— wherein R⁴ can behydrogen or a C₁ to C₆ hydrocarbon; and L can include a polyglycol.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1A illustrates a reaction to form a polymer hydrogel in accordancewith exemplary embodiments of the present invention.

FIG. 1B illustrates a graph of the polymerization kinetics for a polymerhydrogel in accordance with exemplary embodiments of the presentinvention.

FIG. 2 illustrates a stress-strain curve for a developing polymerhydrogel in accordance with exemplary embodiments of the presentinvention.

FIGS. 3 A-D illustrate graphs for in vitro testing of a polymer hydrogelin accordance with exemplary embodiments of the present invention.

FIG. 4 illustrates a chart of dose response of a recombinant Gremlin1 inaccordance with exemplary embodiments of the present invention.

FIGS. 5 A-J illustrate in vivo fluorescence of a GST-647 in accordancewith exemplary embodiments of the present invention.

FIGS. 6 A-C illustrate defect healing in a polymer hydrogel inaccordance with exemplary embodiments of the present invention.

FIGS. 7 A-O illustrate μCT and histology for post operative samples inaccordance with exemplary embodiments of the present invention.

FIGS. 8 A-D illustrate measurements of bone regeneration in accordancewith exemplary embodiments of the present invention.

DETAILED DESCRIPTION

To facilitate an understanding of the principles and features of thevarious embodiments of the invention, various illustrative embodimentsare explained below. Although exemplary embodiments of the invention areexplained in detail, it is to be understood that other embodiments arecontemplated. Accordingly, it is not intended that the invention islimited in its scope to the details of construction and arrangement ofcomponents set forth in the following description or illustrated in thedrawings. The invention is capable of other embodiments and of beingpracticed or carried out in various ways. Also, in describing theexemplary embodiments, specific terminology will be resorted to for thesake of clarity.

It must also be noted that, as used in the specification and theappended claims, the singular forms “a,” “an” and “the” include pluralreferences unless the context clearly dictates otherwise. For example,reference to a component is intended also to include composition of aplurality of components. References to a composition containing “a”constituent is intended to include other constituents in addition to theone named.

Also, in describing the exemplary embodiments, terminology will beresorted to for the sake of clarity. It is intended that each termcontemplates its broadest meaning as understood by those skilled in theart and includes all technical equivalents which operate in a similarmanner to accomplish a similar purpose.

Ranges may be expressed herein as from “about” or “approximately” oneparticular value and/or to “about” or “approximately” another particularvalue. When such a range is expressed, other exemplary embodimentsinclude from the one particular value and/or to the other particularvalue.

By “comprising” or “containing” or “including” is meant that at leastthe named compound, element, particle, or method step is present in thecomposition or article or method, but does not exclude the presence ofother compounds, materials, particles, method steps, even if the othersuch compounds, material, particles, method steps have the same functionas what is named.

In this specification and in the claims that follow, reference will bemade to a number of terms that shall be defined to have the followingmeanings:

As used herein, the term “substituted” is contemplated to include allpermissible substituents of organic compounds. A substituent can includeacyclic and cyclic, branched and unbranched, carbocyclic andheterocyclic, and aromatic and nonaromatic substituents of organiccompounds. The permissible substituents can be one or more and the sameor different for appropriate organic compounds. For purposes of thisdisclosure, the heteroatoms, such as nitrogen, can have hydrogensubstituents and/or any permissible substituents of organic compoundsdescribed herein which satisfy the valences of the heteroatoms. Theterms “substitution” or “substituted with” include the implicit provisothat such substitution is in accordance with permitted valence of thesubstituted atom and the substituent, and that the substitution resultsin a stable compound, e.g., a compound that does not spontaneouslyundergo transformation such as by rearrangement, cyclization,elimination, etc.

The term “hydrocarbon” as used herein is any branched or unbranchedcovalently connected series of carbon and heteroatoms, which can besubstituted or unsubstituted. The hydrocarbon can be fully saturated orunsaturated, and cyclic or acyclic. Categories of hydrocarbons includealkyls, alkenyls, alkynyls, aryls, alkoxys, and so forth.

The term “alkyl” as used herein is a branched or unbranched saturatedhydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl,n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl,isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl,dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and so forth. Thealkyl group can also be substituted or unsubstituted. The alkyl groupcan be substituted with one or more groups including, but not limitedto, substituted or unsubstituted alkyl, cycloalkyl, alkoxy, alkenyl,cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino,carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro,silyl, sulfo-oxo, or thiol, as described herein. A “lower alkyl” groupis an alkyl group containing from one to six carbon atoms.

The term “cycloalkyl” as used herein is a non-aromatic carbon-based ringcomposed of at least three carbon atoms. Examples of cycloalkyl groupsinclude, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, norbornyl, and the like. The term “heterocycloalkyl” is atype of cycloalkyl group as defined above, and is included within themeaning of the term “cycloalkyl,” where at least one of the carbon atomsof the ring is replaced with a heteroatom such as, but not limited to,nitrogen, oxygen, sulfur, or phosphorus. The cycloalkyl group andheterocycloalkyl group can be substituted or unsubstituted. Thecycloalkyl group and heterocycloalkyl group can be substituted with oneor more groups including, but not limited to, substituted orunsubstituted alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl,cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester,ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiolas described herein.

The term “alkoxy” as used herein is an alkyl or cycloalkyl group bondedthrough a saturated carbon-oxygen single bond. “Alkoxy” also includespolymers of alkoxy groups as just described; that is, an alkoxy can be apolyether.

The term “alkenyl” as used herein is a hydrocarbon group of from 2 to 24carbon atoms with a structural formula containing at least onecarbon-carbon double bond. Both the E and Z isomers are considered,unless otherwise specified. The alkenyl group can be substituted withone or more groups including, but not limited to, substituted orunsubstituted alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl,cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester,ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, orthiol, as described herein. “Cycloalkenyl” includes a cycloalkyl havingat least one carbon-carbon double bond within the ring.

The term “alkynyl” as used herein is a hydrocarbon group of 2 to 24carbon atoms with a structural formula containing at least onecarbon-carbon triple bond. The alkynyl group can be unsubstituted orsubstituted with one or more groups including, but not limited to,substituted or unsubstituted alkyl, cycloalkyl, alkoxy, alkenyl,cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino,carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro,silyl, sulfo-oxo, or thiol, as described herein. “Cycloalkynyl” includesa cycloalkyl having at least one carbon-carbon triple bond within thering.

The term “aryl” as used herein is a group that contains any carbon-basedaromatic group including, but not limited to, benzene, naphthalene,phenyl, biphenyl, phenoxybenzene, and the like. The term “aryl” alsoincludes “heteroaryl,” which is defined as a group that contains anaromatic group that has at least one heteroatom incorporated within thering of the aromatic group. Examples of heteroatoms include, but are notlimited to, nitrogen, oxygen, sulfur, and phosphorus. The aryl group canbe substituted or unsubstituted.

The terms “amine” or “amino” as used herein are moieties having a fullysaturated nitrogen with three substituents that are independently,hydrogen or substituted or unsubstituted alkyl, cycloalkyl, alkenyl,cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group describedabove. The term “carboxylic acid” as used herein is represented by theformula —C(O)OH. The term “halide” as used herein refers to the halogensfluorine, chlorine, bromine, and iodine. The term “hydroxyl” as usedherein is represented by the formula —OH. The term “azide” as usedherein is represented by the formula —N₃. The term “nitro” as usedherein is represented by the formula —NO₂. The term “nitrile” as usedherein is represented by the formula —CN.

The term “ester” as used herein is represented by the formula —OC(O)—can be a substituted or unsubstituted alkyl, cycloalkyl, alkenyl,cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group describedabove. The term “amide” as used herein is represented by the formula—N—C(O)—, where the N is fully saturated. The term “carbonate” isrepresented by the formula —OC(O)O—, the term “carbamate” is representedby the formula —OC(O)N—, and the term “urea” is represented by theformula —NC(O)N—. Species that are alternately substituted at the —O—with an —S— will have the prefix “thio-” as recognized by those of skillin the art.

The term “ether” as used herein is represented by the structural moiety—C—O—C— where each C is independently a carbon of a hydrocarbon, such asa substituted or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl,alkynyl, cycloalkynyl, aryl, or heteroaryl group as previouslydescribed.

The term “polyether” as used herein is a series of repeating ether unitsthat are either the same or different from one another, and having arepeating unit that is an integer of from 1 to 500

The term “polyglycol” as used herein indicates a category of polyethercompounds, and includes a repeating chain of substituted orunsubstituted polyethylene glycol units, including polyethylene glycol(PEG) (also called polyethylene oxide or PEO), polypropylene glycol(PPG) (also called polypropylene oxide or PPO) and other substitutedpolyethylene glycol. The term “glycol” as used herein indicates asubunit of the polyglycol, e.g. polyethylene glycol has a glycol subunitof —CH₂—CH₂—O—.

Reference will now be made in detail to specific aspects of thedisclosed materials, compounds, compositions, articles, and methods,examples of which are illustrated in the accompanying Examples andFigures.

The present inventive composition can include a polymer hydrogel whichcan be described by the structure shown in Formula I:

Alternatively, the polymer hydrogel can also be described by as havingat least two parts, a polyacrylate backbone as shown by Formula II

and a crosslinking member as shown by Formula III

The polyacrylate backbone and the crosslinking member can be connectedeither directly or via an intervening substituent. In an exemplaryembodiment, the crosslinking member and the polyacrylate are connectedthrough the triazole ring.

In the polymer hydrogel as well as and its precursors and components asset forth throughout the specification herein, R¹ and R² can each beindependently hydrogen or a C₁ to C₆ hydrocarbon, preferably hydrogen ormethyl; R³ can be hydrogen or methyl; X can be —O—, —S—, or —NR⁵—,preferably O, and Z can be —OR⁶, —SR⁶, or NR⁵R⁶, preferably —OR⁶; withR⁵ as hydrogen or C₁ to C₆ hydrocarbon and R⁶ as hydrogen, C₁ to C₆hydrocarbon or a polyglycol chain of two to ten glycol units.

In the polymer hydrogel as well as its precursors and components as setforth throughout the specification herein, m can be an integer greaterthan or equal to 1, including between 1 and 20 inclusive, between 1 and10 inclusive, greater than or equal to 2, between 2 and 10 inclusive,between 2 and 8 inclusive, between 2 and 6 inclusive, and between 3 and6 inclusive.

In the polymer hydrogel as well as its precursors and components as setforth throughout the specification herein, each R¹⁰, R¹¹, R¹², R¹³,R^(10′), R^(11′), R^(12′), R^(13′) can independently be hydrogen, C₁ toC₆ alkyl, C₁ to C₆ alkoxy, nitro, fluoro, chloro, or bromo, preferablyhydrogen or fluoro, or alternatively hydrogen only. Y¹ and Y² can eachindependently be —O—, —S—, or —NR⁴— wherein R⁴ can be hydrogen or a C₁to C₆ hydrocarbon, and alternatively Y¹ and Y² can each independently be—O— or —NR⁴, and preferably Y¹ can be O and Y² can be NH. Alternatively,Y¹ can be NH and Y² can be O.

In the polymer hydrogel as well as its precursors and components as setforth throughout the specification herein, L can contain a polyglycol,preferably a polyethylene glycol, a polypropylene glycol, or a mixtureof a polyethylene glycol and a polypropylene glycol.

In the polymer hydrogel as well as its precursors and components as setforth throughout the specification herein, x can be an integer greaterthan zero; and z can be zero or an integer greater than zero. A ratio ofx to z can be described when z is a non-zero integer. In an embodiment,the ratio of x to z can be less than or equal to about 50:1. The ratioof x to z can also be greater than or equal to about 1:10. In anembodiment, the ratio of x to z is between about 50:1 to about 1:5,alternatively about between about 10:1 to about 1:1. In an exemplaryembodiment, the ratio of x to z can be between about 5:1 to about 2:1.

The polyacrylate backbone can be described as being formed by thepolymerization of one or more of an acrylic acid compound, such as anacrylic acid, an acrylic ester, an acrylic amide, or the like. Theacrylic acid compound may be substituted at any position on the alkenebond by one or more hydrocarbons, such as H₂C═CH—C(O)—, RHC═CH—C(O)—,RR′C═CH—C(O)—, RR′C═CR″—C(O)—, RHC═CR′—C(O)—, or H₂C═CR—C(O)—. Anymonomer unit containing an acrylate or di-acrylate may be incorporatedinto the polymer backbone to generate a multifunctional polymer supportfor drug delivery and or cell attachment.

The polyacrylate backbone can be prepared from one or more differentacrylic acid compounds. In an embodiment, the polyacrylate backbone canbe formed from a single acrylic acid compound, and could be a compoundof Formula VII:

wherein R¹, R³, X and m are as described above. In another embodiment,the polyacrylate backbone can be described as being formed by thepolymerization of two acrylic acid compounds, and would be a compound ofFormula II. One of ordinary skill in the art would recognize that theacrylic acid compounds would be randomly polymerized within thepolyacrylate backbone. In yet another embodiment, the polyacrylatebackbone can be described as being formed by the polymerization of threeor more acrylic acid compounds, for example as shown for a compound ofFormula VIII

wherein R¹, R², and R⁷ can each be independently hydrogen or a C₁ to C₆hydrocarbon; R³ can be hydrogen or methyl; Z and Z′ can eachindependently be —OR⁶, —SR⁶, or NR⁵R⁶; m can be an integer greater thanor equal to 1; x can be an integer greater than zero, z and z′ can eachindependently be an integer greater than zero; R⁵ can be hydrogen or C₁to C₆ hydrocarbon; R⁶ can be hydrogen, C₁ to C₆ hydrocarbon or apolyglycol chain of two to ten glycol units, ending in a free hydroxylor a terminal C₁ to C₄ ether.

In an exemplary embodiment, the polyacrylate backbone can have an R¹that can be hydrogen or methyl, an R² when present that can be hydrogenor methyl, and R⁷ when present that can be hydrogen or methyl.

In an embodiment of the present invention, the polyacrylate backbone ofthe polymer hydrogel can have at least one polyglycol chain, describedby the portion of the structure pendant to the X. i.e. —OCH₂CHR³—, asexemplified in at least Formulas I and II. In an embodiment, thepolyglycol chain can be described by the glycol repeating structuredefined by m. In an embodiment, m can be an integer greater than orequal to 1. In an embodiment, m can also be less than or equal to 20. Inan exemplary embodiment m can be from 2 to 20 inclusive, from 2 to 15inclusive, from 2 to 10 inclusive, or from 2 to 8. In another exemplaryembodiment, m can be from 3 to 10 inclusive, 3 to 8 inclusive, from 3 to7 inclusive, or from 3 to 6 inclusive.

When the polyacrylate backbone contains two acrylate acid compoundsubunits, as in for example Formula I or II, Z can be —OR⁶, —SR⁶—, orNR⁵R⁶ and R⁶ can be hydrogen, C₁ to C₆ hydrocarbon or a polyglycol chainof two to ten glycol units. In an embodiment, R⁶ can be hydrogen or C₁to C₆ hydrocarbon. In another embodiment, R⁶ can by a polyglycol chainof two to eight glycol units, or a polyglycol chain of three to sixglycol units.

When R⁶ is a polyglycol, then R⁶ can end in a free hydroxyl, amine,terminal C₁ to C₄ ether, ester, amide, carbonate, carbamate, or urea,preferably a free hydroxyl or terminal ether, more preferably as a freehydroxyl.

When the polyacrylate backbone is prepared from at least two acrylicacid compounds, the polyacrylate backbone will include a ratio of thetwo acrylic acid compounds, which can also be described in at leastFormulas I and II as a the ratio of x and z. In an embodiment, the ratioof x to z can be less than or equal to about 50:1. The ratio of x to zcan also be greater than or equal to about 1:10. In an embodiment, theratio of x to z is between about 50:1 to about 1:5, alternatively aboutbetween about 10:1 to about 1:5, or from about 10:1 to about 1:1. In anexemplary embodiment, the ratio of x to z can be between about 5:1 toabout 1:1, or about 5:1 to about 2:1. In the case where the polyacrylatebackbone is prepared with three or more acrylic acid compounds, as inFormula VIII above, z′ is understood to be part of z for purposes ofdetermining the ratio.

The polyacrylate backbone can include X as —O—, —S—, or —NR⁵— and Z as—OR⁶, —SR⁶, or NR⁵R⁶ when z is a non-zero integer. When X or Z areoxygens, the moiety can be described as an ester, and the acrylic acidcompound that serves as a precursor would be described as an acrylateester. When X or Z are nitrogens, i.e. NR⁵, the moiety can be describedas an amide and the acrylic acid compound that serves as a precursorwould be described as an acrylate amide or acrylamide.

The crosslinking member can be a structure as shown by Formula III

where each R¹⁰, R¹¹, R¹², R¹³, R^(11′), R^(11′), R^(12′), R^(13′) caneach independently be hydrogen, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, nitro,fluoro, chloro, or bromo; Y¹ and Y² can each independently be —O—, —S—or —NR⁴— wherein R⁴ can be hydrogen or a C₁ to C₆ hydrocarbon; and L cancontain a polyglycol. The crosslinking member can be further describedas generally having two subunits—a pair of triaza-bis-benzo-cyclooctenylring systems and a bridging polyglycol portion that also contain thecarbonyl groups. Because each crosslinking member has two subunitscomposed of the triaza-bis-benzo-cyclooctenyl ring systems, each sidecan bind to a polyacrylate backbone portion. One of ordinary skill willrecognize that the specific polyacrylate backbone that is bound on eachend of the crosslinking member can be portions of the same polyacrylatemolecule or can be from different polyacrylate molecules.

In a preferred embodiment, each of R¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′),R^(12′), R^(13′) can be hydrogen. In an alternate embodiment, one ormore R¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′), R^(12′), R^(13′) can eachindependently be fluoro and the remaining can be hydrogen.

The combination of Y¹, Y² and the carbonyl group can be described as acarbonate when both Y¹ and Y² are oxygen, a carbamate when Y¹ or Y² isoxygen and the other is NR⁴, or a urea, when both Y¹ and Y² are NR⁴. Inone embodiment, the combination of Y¹, Y² and the carbonyl group is acarbamate. In another embodiment, the combination of Y¹, Y² and thecarbonyl group is a carbonate. In instances where a sulfur is present aseither Y¹ or Y², the thio prefix can be applied. One advantage in thesecompositions is that the degradation of the polymer hydrogel can bemodified based on chemical groups that are incorporated into thesehydrogels. For example, the use of the carbonate with Y¹ and Y² eachbeing oxygen allows for easier degradation and faster release than ifone or both of Y¹ and Y² are nitrogens. In an exemplary embodiment, Y¹is an O and Y² is NR⁴.

In an embodiment of the present invention, the structure L can contain apolyglycol. The polyglycol can be composed of 10-1000 glycol subunits,20-500 glycol subunits, or 20 to 200 glycol subunits. Alternatively, thepolyglycol can be composed of 10-150 glycol subunits, 50-200 glycolsubunits, or 75-350 glycol subunits. Determination of the polyglycollength can be varied depending on the application to which the polymerhydrogel is being applied. The polyglycol portion of L can also bedescribed by a molecular weight number, M_(w), of between about 500 andabout 10000, between about 1000 and about 8000, or between about 1500and about 7500. The glycol subunit can be an ethylene glycol, apropylene glycol, or a high alkyl glycol. In an embodiment, the glycolsubunit is an ethylene glycol or a propylene glycol, preferably anethylene glycol. The glycol subunit can also be a mixture of two or moreglycols, for example ethylene glycol and a propylene glycol.

In an embodiment, the structure L can contain the polyglycol and one ormore additional chemical moieties within the polyglycol chain. Thestructure L can include one or more additional chemical moieties thatcan be esters, amides, carbonates, carbamates, or ureas. For example, anL containing a polyethylene glycol and a carbonate structure might havea formula such as [(CH₂CH₂O)_(p)C(O)O—]_(q)—. Similarly, the unit couldinstead include carbamates, ureas, amides or esters, or a combinationthereof. Including these moieties can allow further tailoring of thedegradation or stability of the polymer hydrogel when used in abiological environment. Stimuli responsive units can also beincorporated into L, and would allow the hydrogels to degrade inresponse to cellular signals such as enzyme production or ph changes.

In Formula III, as well as several other formulas, the connectivity ofY¹ to the triazacyclooctene ring is not specified, due to the nature ofthe bond formation for the alkyne and azide, as discussed below. One ofskill in the art would recognize that the two open carbon positions arenot chemically equivalent, due to at least the relative position of thebond off of the triazole ring. In the polymer hydrogel, both of thesepositions might be occupied by the bond to Y¹ as shown below.

In an exemplary embodiment of the present invention, the polymerhydrogel can have a structure of formula IX

wherein, R¹ and R² are each independently hydrogen or a C₁ to C₆hydrocarbon, x is an integer greater than zero, z is zero or an integergreater than zero, m is greater than or equal to 2, X is —O— or —NR—, Zis OR⁶ or NHR⁶, wherein R⁶ is hydrogen, C₁ to C₆ hydrocarbon or apolyglycol chain of two to ten glycol units, Y¹ is —O—, Y² is —NH—, andL comprises a polyethylene glycol. In another embodiment, R¹ and R² areeach independently hydrogen or methyl, x and z are integers greater thanzero, X is O; Y¹ is —O—, Y² is —NH—, and Z is OR⁶, wherein R⁶ is apolyethylene glycol of two to ten ethylene glycol units, and L comprisesa polyethylene glycol of 10 to 100 ethylene glycol units.

The polymer hydrogels of the present invention can be formed by a [3+2]cycloaddition reaction between an alkyne and an azide. In a embodiment,a method of making the polymer hydrogels can include the reaction of apolyacrylate azide of Formula IV

and a crosslinking alkyne of Formula V

where R¹, R², R³, X, m, x, z, R¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′),R^(12′), R^(13′), Y¹, Y² and L are as defined above. The reaction can beconducted in aqueous solution. The reaction and the resulting polymerhydrogel do not require or contain a metal salt, particularly a coppersalt.

This two component system contains the alkyne and the azide which uponmixing react via a [3+2] cycloaddition to form a triazole ring thatcovalently crosslinks the components and forms the polymer hydrogel.Significantly, this reaction, commonly described as click chemistry,does not require a metal catalyst. Traditional reactions involvingsimilar [3+2] cycloadditions have relied on a catalyst, typically CuI toundergo reaction at any significant rate. The classical Cu-catalyzedHuiseng cyclo-addition has been used to crosslink azide and alkynes, butthe toxicity associated with the copper catalyst diminishes the clinicalviability of such systems. Recently a copper-free [3+2] cycloaddition ofa hydrogel composed of an azide-terminated PEG and a polypeptidefunctionalized with difluorinated cyclooctyne was demonstrated. However,that reaction took approximately one hour to achieve completepolymerization. In comparison, the polymer hydrogels of the presentinvention can achieve gelation in less than thirty seconds andcompletely polymerize in less than ninety seconds due at least in partto the ring-strain associated with the dibenzocyclooctynyl ring. Thus,the present reaction is nearly two orders of magnitude faster. Theresulting triazole ring connects the polyacrylate azide and thecrosslinking alkyne to produce the polymer hydrogel at rates that aremuch more useful for biological applications. Moreover, the reactionoccurs in aqueous conditions, making it very valuable for in vivobiological applications, and the rapid reaction can rapidly encapsulateco-administered therapeutic agents before they can diffuse away from aninjection site.

In an embodiment of the present invention, compositions for the polymerhydrogel containing the an crosslinking alkyne and a polyacrylate azidecan reach complete polymerization in less than about 3 minutes,preferably less than about 2 minutes, and more preferably less thanabout ninety seconds. In an embodiment of the present invention,compositions for the polymer hydrogel containing the an crosslinkingalkyne and a polyacrylate azide can achieve gelation in less than about1 minute, preferably less than about 45 second, and more preferably lessthan about 30 seconds. The complete polymerization and gelation areterms understood by one of ordinary skill in the art, and are ameasureable value using standard techniques. The polymer hydrogels canachieve gelation and polymerization in these time frames either in vitroor in vivo, making the polymer hydrogels very effective in a clinicalsetting.

Because of the rapid gelation and polymerization of the polymer hydrogelof the instance invention, therapeutic agents can be included in thepolymer hydrogel for treatments in a biological system. Therapeuticagents can include biologically active agents, biological agents,macromolecules, therapeutic molecules, and similar compounds as one ofordinary skill in the art would recognize. This may also includeproteins, peptides, nucleic acids, or other small molecules. In anembodiment of the present invention, a therapeutic agent can be presentin the compositions containing polymer hydrogel. The therapeutic agentcan be encapsulated or absorbed in the polymer hydrogel. The therapeuticagent need not be chemically bonded to the polymer hydrogel. In anexemplary embodiment, the composition can contain a protein or nucleicacid, preferably a protein. The composition can contain a protein thatis between about 5 to 100 kDa, or about 10 to about 50 kDa, or about 15to about 35 kDa. Alternatively, the composition can contain as atherapeutic agent a pharmaceutical drug, commonly termed small moleculeto distinguish from macromolecules. In an exemplary embodiment, thetherapeutic agent can be included with the components that form thepolymer hydrogel prior to the [3+2] cycloaddition. Thereby, thetherapeutic agents can be delivered by the polymer hydrogel, or thepolymer hydrogel can localize the therapeutic agents to a specificlocation. Moreover the polymer hydrogel can also be used as a scaffoldto deliver or incorporate cells to a specific location.

Because of the nature of the polymer hydrogel synthesis and itssynthetic components, an embodiment of the present invention can be akit for a therapeutic treatment, where the kit contains an aqueoussolution of a polyacrylate azide such as Formula IV above, an aqueoussolution of a crosslinking alkyne such as Formula V above, and anaqueous solution of a therapeutic or biologically active agent. In anembodiment, the polyacrylate azide the kit can be a structure of FormulaX

wherein R¹ and R² are each independently hydrogen or methyl, m is aninteger between 1 and 20, n is an integer between 1 and 20, and x and zare as defined above. In an embodiment, m and n can each independentlybe an integer greater than or equal to 1, including between 1 and 20,inclusive, between 1 and 10 inclusive, greater than or equal to 2,between 2 and 10 inclusive, between 2 and 8 inclusive, between 2 and 6inclusive, and between 3 and 6 inclusive.

In an embodiment, the crosslinking alkyne in the kit can be a structureof Formula XI

where L is as defined above. In another embodiment, the crosslinkingalkyne in the kit can be a structure of Formula XII

wherein o is an integer between 10-100.

In an embodiment, the aqueous solution of the crosslinking alkyne cancontain about 0.5% to about 20% w/v alkyne in water, preferably about 1%to about 15% w/v of alkyne in water, and more preferably about 1.5% toabout 12.5% w/v of alkyne in water.

The compositions containing the polymer hydrogel can contain asubstantial amount of water, as typical of hydrogels. This water contentprovides the polymer hydrogel with it ability to deliver therapeuticagents to a location while still maintaining its structure andcharacteristics. In an embodiment, the polymer hydrogel can have aconcentration in water of between about 0.5% and 25%, preferably betweenabout 1% and about 20%, more preferably between about 1.5% and about15%, and even more preferably between about 1.5% and about 12.5%, allexpressed in w/v of the polymer hydrogel in water.

Compositions of the polymer hydrogel can have numerous biologicalapplications. In an embodiment, the polymer hydrogel can be used foraiding the healing or therapeutic treatment of a tissue, such as, forexample, skin tissue, muscle tissue, bone, and any other biological areathat can benefit from the localized and/or controlled delivery of atherapeutic agent. Moreover, the polymer hydrogels are tunable due tothe different portions of the structure. Sections that can be variedinclude at least the polyglycol, which can be varied in length andglycol unit; the nature of the polyacrylate, by for example increasingor decreasing the portion of azide present to increase or decrease theamount of crosslinking in the hydrogel; varying the composition of thenon-crosslinking portion of the polyacrylate to vary the environmentwithin the gel; and so forth. With these tunable controls, thecharacteristics of polymer hydrogels can be changed to, for example,make the polymer hydrogel stiffer or more flexible, thereby matching thecharacteristics of the tissue to which it is being applied.

By way of example, the compositions having polymer hydrogel can be usedto control the healing of bone defects, which are some of the mostfrequent and difficult challenges in medicine. These compositions canprovide an in-situ polymerizing drug delivery scaffold for themodulation of bone healing. The therapy can designed for both long boneand calvaria defects, and can also be applied to a wide range of otherapplications.

In an exemplary embodiment of the present invention, the compositions ofhaving the polymer hydrogel can be used to treat craniosynostosis.Craniosynostosis is the premature fusion of the cranial suture early indevelopment. If left untreated it can lead to blindness, deafness, anddevelopmental delays. The current treatment for more severe cases is thesurgical removal of the fused suture and/or remodeling of the skull. Inup to 40% of these surgeries the skull re-fuses prematurely,necessitating a second surgery to correct the re-fusion. This secondsurgery is associated with an incredibly high incidence of morbiditiesand mortalities. Despite the clinical need for a therapy to delay thehealing of the cranial defect there is no therapy to delay there-closure.

The polymer hydrogel disclosed herein can address these limitations byproviding a tunable biodegradable scaffold to provide a controlledrelease of proteins, peptides, nucleic acids, or other small molecule todelay the formation of bone. In an embodiment of the present invention,the compositions can be used to deliver of proteins or theircorresponding peptides to inhibit osteoblast differentiation such as,but not limited to, Noggin, Gremlin 1, and Sclerostin. Previous researchhas shown that the mineralization of this defect was associated with anincrease in mRNAs for bone morphogenic protein (BMP) 2 (Bmp2), BMP-4(Bmp4), and the BMP inhibitor Gremlin1 (Grem 1). BMP inhibitors likeGremlin1 are normally secreted to bind to their respective targetsextracellularly as part of a negative feedback control system. As aresult, these inhibitors are attractive therapeutic agents as they canalter BMP-dependent intracellular signaling without having to cross thecell membrane.

The polymer hydrogel based therapy disclosed herein can be designed toprovide a delivery vehicle for proteins or other factors forcraniosynostosis. One of the advantages of this polymer hydrogel is thatit spontaneously polymerizes without the production free radicals or theneed for metal catalysts such as copper, which is of particular concernin this application. There are no chemical solvents or initiatorsinvolved in the polymerization. The polymer hydrogel also has theadvantage that the two components can be injected as liquids andpolymerize in-vivo. This polymerization can take place in saline as wellas in environments that contain blood.

The invention can also be used as a delivery vehicle for the promotionof long-bone or calvarial defects. This may be accomplished by thedelivery of proteins, peptides, nucleic acids, or other small molecules.The polymer hydrogel can also be used as a cell delivery scaffold. Thiscan be performed with either encapsulated cells or incorporation of thecells in a larger scaffold. The polymer has also been functionalizedwith the RGB peptide to deliver BMP2 and deferoxamine. The deferoxamineis a drug that up-regulates HIF which is associated with apro-angiogenic response. The polymer hydrogel can also serve as ascaffold for other molecules to promote osteoblast differentiation thatinclude but are not limited to BMP4, BMP7, etc. Additionally, thepolymer hydrogel could include other pro-angiogenic factors designed topromote bone in-growth into the scaffold, such as but not limited toVEGF.

Thus, in an embodiment of the present invention, the therapeutic agentcan be an agent that is used to treat bone, bone tissue, or an area nearbone tissue. The therapeutic agent can be an agonist, antagonist,inhibitor or activator of enzymes or biological processors related tobone growth and development. The therapeutic agent can target theregulation of the BMP family of proteins, particularly an inhibitor orantagonist of BMP. In one exemplary embodiment, the compositions andmethods containing the polymer hydrogel can include a recombinantprotein that inhibits BMP, preferably a recombinant proteins of Gremlin,Noggin, or Sclerostin. In an alternative embodiment, the polymerhydrogel can deliver a therapeutic agent that aids and encourages bonegrowth and development. In one exemplary embodiment, the composition cancontain deferoxamine.

While the polymer hydrogel can be used for craniofacial and orthopedicapplications, there are numerous other uses. The polymer hydrogel canserve as a scaffold for delivery of bioactive molecules for dentalapplications to regenerate lost bone. The polymer hydrogel can also beused to deliver antibiotics to treat osteomyleitis, open skin ulcers, orother infections. The polymer hydrogel has also serve as a scaffold forthe repair of large muscle defects or crush injuries, particularly wheredelivery of a localized therapeutic agent is desired for the treatment.

Thus, in another embodiment of the present invention, a therapeuticagent can be administered to an anatomical part of the body that wouldbenefit from localized delivery of the therapeutic agent.

The various embodiments of the present invention are further illustratedby the following non-limiting examples.

EXAMPLES Synthesis of Polymer Hydrogel

Synthesis of poly[Tetraethylene glycolmethacrylate)-co-(azidotetraethylene glycol methacrylate)] (PEG-N3) wasprepared by combining tetraethylene glycol methacrylate (0.9 g, 3.43mmol) and azido tetraethylene glycol methacrylate (0.28 g, 1.0 mmol),micro RAFT agent (benzothioylsulfanyl)acetic acid (6.27 mg, 0.03 mmol),and AIBN (0.5 mg, 0.003 mmol) in dimethylformamide (1.5 ml). Thereaction flask was degassed by five freeze-pump-thaw cycles, and thenimmersed in an oil bath and stirred at 70° C. After 20 h, the reactionwas terminated by flash freezing the in liquid nitrogen. The reactionproduct was added to DCM (5 ml) and then precipitated from methanol (25ml). The supernatant was decanted and the precipitated polymer wassubjected to three more rounds of resuspension and precipitation beforebeing concentrated under reduced pressure. The purified polymer wasanalyzed for weight by gel permutation chromatography (tetrahydrofuran)and the structure and purity were verified by ¹H NMR (deuteratedchloroform).

Varying the relative concentration of a dibenzocyclooctynyl compound(“DBCO-PEG”) analogous to Formula XII, where L is a polyethylene glycolhaving approximately 75 ethylene glycol units prior to polymerizationallowed for the formation of gels with highly customizable properties.FIG. 1A shows the reaction of a polyacrylate azide (PEG-N3) with aDBCO-PEG, a crosslinking alkyne, to form a 3D ideal network hydrogel.Aqueous stock solutions of DBCO-PEG (12.5%, 6.25%, 4.85%, 3.13%, 1.56%;w:v) and PEG-N3 (50%; w:v) were used to form cylinders for unconstrainedcompression testing. Spinning disk rheometry showed that when theDBCO-PEG and PEG-N3 solutions were combined the gel point occurred inless than 25 seconds and complete polymerization occurred in less than90 seconds, as shown in FIG. 1B. As with most hydrogels, the geldisplayed a highly non-linear behavior in response to compression, whichmakes assumptions used with traditional engineering materials invalid.The Neo-Hookean hyperelastic constitutive equations were able toaccurately model the stress-strain response of the gels, as shown inFIG. 2. The gel has random polymerization and has a relatively highwater content, which allows for the assumption that the gels are bothisotopic and incompressible. These assumptions allow the originalconstitutive equations to be simplified and allow the Neo-Hookeancoefficient (C₁) to be found in terms of the stretch ratio (λ) and theengineering stress in the axial direction (σ_(1i) ^(eng)):

$\sigma_{11}^{eng} = {2{{C_{1}\left( {\lambda - \frac{1}{\lambda^{2}}} \right)}.}}$

Unconstrained compression testing showed that increasing theconcentration of the DBCO-PEG resulted in an increase in the mechanicalproperties of the polymer hydrogel. FIG. 3A show the Unconstrainedcompression testing of hydrogel using a Neo-Hookean hyperelastic modelshowed that increasing the concentration of the DBCO-PEG resulted in anincrease in the Neo-Hookean coefficient (C1). *=p<0.05 vs 12.5%. FIG. 3Bshows the in vitro release of GST-647 from hydrogels with increasingconcentrations of DBCO-PEG that resulted in a more prolonged and linearrelease profile with the 12.5% gel having controlled release out to 14days. FIG. 3C shows that degradation of the 12.5% gel assessed byunconstrained compression had a decrease in the Neo-Hookean coefficientafter day 7. *=p<0.05 vs day 0. FIG. 3D shows that the biologicalactivity of rmGremlin1 was retained after release followingpolymerization in the hydrogel as assessed by blocking the rhBMP-2mediated increase in alkaline phosphatase specific activity *=p<0.05 vscarrier, #=p<0.05 vs rhBMP2

At the lowest concentration, the Neo-Hookean coefficient was less than0.3 then increased to approximately 2 for the mid concentrations, andthen finally peaked at over 5 for the 12.5% DBCO-PEG (FIG. 3A). For the12.5% gel this corresponds to a Young's modulus of approximately 32 kPA.Hydrogels with concentrations less than 1.5% or greater than 12.5% didnot polymerize (data not shown). Increasing the concentration of theDBCO-PEG also resulted in a more linear and prolonged release ofincorporated proteins.

Release Kinetics

In order to assess release kinetics, prior to polymerization, 12.5%hydrogels were loaded with glutathione s-tranferase (GST) labeled withan Alexa fluor carboxylic acid fluorophore (GST-647) as a model protein.This GST-647 complex has a molecular weight that is nearly identical tothat of the BMP inhibitor Gremlin dimer. GST-647 loaded hydrogels wereincubated for up to two weeks in sterile PBS with 10% FBS at 37° C.Measuring the total fluorescent signal showed that 12.5% hydrogels withthe greatest concentration of cross-linker had the slowest release ofGST-647 at all time points examined (FIG. 3B). Hydrogels withprogressively lower cross-linking concentrations had a more rapid andnon-linear release of incorporated protein with the 3.1% gel releasingnearly 75% of the protein after only 1 day while the 12.5% gel released75% of proteins out to 10 days (FIG. 3B). The degradation of the 12.5%hydrogel showed that the compressive moduli were retained for 3 days ofincubation, before gradually decreasing for the remaining time points(FIG. 3C).

In Vitro Testing

Experiments using rmGremlin were performed to verify that proteinsreleased from the polymer hydrogel can retain their biological activityfollowing in situ polymerization. Gremlin is a traditional BMPantagonist and blocks the activity of BMP-2, BMP-4, and BMP-7. Aconditioned media model was established in which pre-osteoblastic MG63cells were treated with rhBMP2 and their differentiation monitored as afunction of increased alkaline phosphatase specific activity. Apreliminary dose-response study showed that 100 ng/mL rmGremlin1 wasable to block the effect of rhBMP2 on this cell line. FIG. 4 shows thatthe dose-dependent effects of rmGremlin1 on ability of rhBMP2 to inducethe differentiation of MG63 cells (rhBMP2 was added when cells were 80%confluent). There was an increase in alkaline phosphatase specificactivity in response to rhBMP2 and this effect was blocked by theaddition of rmGremlin1 in a dose dependent fashion. #=p<0.05 vs Carrier,$=p<0.05 vs BMP2. and that it was necessary to incubate hydrogelscontaining 100 ng/mL rmGremlin1 in the culture medium for 7 days toachieve release of the incorporated protein. Accordingly, hydrogelscontaining either rmGremlin1 or the vehicle control were incubated inthe co-culture dishes for 7 days, at which time 100 ng/mL rhBMP2 wasadded to the well. Enzyme activity was measured 24 hours later. Cellstreated with rhBMP2 alone or with the polymer hydrogel containing thermGremlin1 vehicle (4 mM HCl) exhibited a 20% increase in alkalinephosphatase activity over control cultures, as shown in FIG. 3D.However, if rmGremlin1 was either injected into the medium or wasreleased from the polymer hydrogel following in situ hybridization, therhBMP1-dependent stimulation was reduced to control levels, as shown inFIG. 3D.

In Vivo Release Kinetics and Defect Healing

After verifying that the polymer hydrogel can provide controlled releaseof proteins that retain their biological activity following in situpolymerization, the in vivo release kinetics of a polymer hydrogel wereassessed in the infant PF suture defect model. Following creation of thedefect over the PF suture in 21 day old pups, mice were randomized for a2 μL injection of either GST-647 in un-polymerized PEG-N3 or with the12.5% hydrogel containing GST-647. For the latter experimental group,equal volumes of PEG-N3, DBCO-PEG, and the GST-647 were chilled on ice,mixed rapidly, and then injected into the defect. As the gels have a lowviscosity prior to polymerization, the solution was able to fill theentire defect and then rapidly polymerize in situ, creating a stable gelin less than 90 seconds.

FIGS. 5 A-J show the in vivo fluorescence release of GST-647 kineticsfollowing in situ polymerization of hydrogel. Fluorescent image of micewith GST-647 in cross linked hydrogel showed a controlled and localizedsignal over the defect out to 14 days post-op, as shown in FIGS. 5 A-D.In contrast the signal of the group containing the un-polymerized PEG-N3showed that the protein rapidly diffused out of the defect and there wasvery little signal after post-op day 5, as shown in FIGS. 5 E-H.Quantification of the total fluorescent signal over the entire headshows that after day post-op day 2 there is more signal in the hydrogelgel group and there is only a slight decrease in the total fluorescentsignal, as shown in FIG. 5 I, *=p<0.05 vs day 2, #=p<0.01 vs hydrogel.Comparing the ratio between the fluorescent signal in the defect to thetotal signal showed that the hydrogel groups had a higher value forpost-op days 2 to 14, indicating that the hydrogel had a more controlledrelease of incorporated protein, as shown in FIG. 5 J, *=p<0.05 vs day0, #=p<0.05 vs hydrogel.

When the polymer hydrogel was injected in the defects for in situpolymerization, the fluorescent signal remained localized within thesite of the defect for all time points and decreased gradually over time(FIGS. 5 A-D). In contrast, the fluorescent signal in animals containingthe un-polymerized PEG-N3 showed that the protein diffused out of thedefect by 2 days post-op and there was essentially no signal seen ondays 5 and 14 post-op (FIG. 5E-H). Quantification of the totalfluorescent signal over the entire head of the animals showed nodifferences for the first two time points, but there was less signal inthe PEG-N3 mice for the later time points on post-op days 5 and 14 (FIG.5 I). Additionally, the ratio between of signal contained within thedefect to the total signal detected was approximately 1 for the polymerhydrogel groups, indicating that essentially all of the fluorescentproteins were localized to the defect (Figure F J). The groupscontaining just the un-polymerized PEG-N3 began at a ratio ofapproximately 1, but this more than doubled for the remaining timepoints as the proteins continued to diffuse away from the defect site.

To verify that the in situ polymerization of the polymer hydrogel wasnot toxic to the surrounding tissues, mice were randomized to have anempty cranial defect or injected with the polymer hydrogel containingPBS only. The extent of bone regeneration was imaged by micro-computedtomography (μCT) on post-operative days 2, 5, and 14 and the imagesquantified using advanced image processing algorithms developed by uspreviously to segment bones of varying and heterogeneous mineral contentthat are seen in the healing of the pediatric specific model 21. FIGS. 6A shows that at 5 days post-op there was a slight decrease in the defectwidth in the empty defect, but there were no difference on day 14. FIGS.6 B and C show that In groups with the hydrogel there was slightly lesstotal mineral content and bone volume on both post-op days 2 and 5 butno differences by post-op day 14. *=p<0.05 vs empty.

There was a transient reduction in the bone within defect treated withpolymer hydrogel alone. By 14 days post-op there were no differences ineither the average defect width or the volume of bone in the defect.This indicates that the polymer hydrogel has a space occupying effectearly, but that in vivo the gel is degraded or replaced by theregenerating bone.

Polymer Hydrogel to Inhibit Re-Synostosis

The hydrogels are able to provide a highly localized, controlleddelivery of incorporated proteins in vivo and do not have a long termimpact on bone regeneration. To demonstrate that incorporated proteinscan have a biological effect in vivo, the polymer hydrogel was used todelay post-operative bone growth following PF suturectomy by deliveringthe BMP inhibitor rmGremlin1 in a cranial defect model. Re-synostosisfollowing suturectomy of the PF suture in infant mice is associated withan increase in expression of mRNAs for Bmp2, Bmp4 and Grem. In addition,Gremlin it has been previously shown to be more specific against BMP2and BMP4 than other antagonists. Cranial defects were created in 21 dayold mice (5 mice per group per time point) and randomized to both thepost-operative time point and whether the defect contained one of thefollowing treatments: empty defect, hydrogel+vehicle, hydrogel+300 ngrmGremlin1, hydrogel+500 ng rmGremlin1, un-polymerized PEG-N3+500 ngrmGremlin1. Mice were euthanized and imaged with μCT and decalcifiedhistology on post-op days 5 and 14.

Empty defects contained a very thick trabeculated structure that wasvisible on both the μCT and histology images at 14 days post-op. Thedefects were nearly completely bridged as shown in the 3D rendering,similar to what was observed previously, as shown in FIGS. 7 A-C.Defects containing the polymer hydrogel had this same thick trabecularstructure, but there was not complete bridging at the center, as shownin FIGS. 7 D-F. The 3D rendering showed that this small gap occurred inonly a very small region and the majority of the defect was healed, asshown in FIG. 7 D. Histology showed disorganized fibrous connectivetissue between the bones of the defect, as shown in FIG. 7 F. Hydrogelscontaining rmGremlin1 caused a dose dependent decrease in the amount ofbone present in the defect, as shown in FIGS. 6 G-L. None of theseanimals displayed bridging of the defect and histology showed morefibrous connective tissue within the defect, as shown in FIGS. 7 I andL. Additionally, the 2D μCT images showed a lack of the thick trabecularstructure that was seen in the empty or hydrogel+carrier defects, asshown in FIGS. 7 H and K. The defects containing the un-polymerizedPEG-N3 also had nearly completed bridging of the defect and the thicktrabecular structure that was seen with the empty defects, as shown inFIGS. 7 M-O, indicating that the highest dose of rmGremlin1 did not haveany effect on defect healing in the absence of a cross-linked gel.

Quantification of Defect Healing

The extent of bone regeneration was assessed using μCT and an advancedsegmentation algorithms described above. On post-op day 5 there was adecrease in the defect width, a slight decrease in the distance for thehydrogel+carrier group, but for both of the groups containing rmGremlin1there was no decrease in the distance from the initial 1.50 mm widedefect, as shown in FIG. 8 A. By 14 days post-op there was a decrease inthe width for both the hydrogel+carrier and lower dose hydrogel+300 nggroup, but there was no change in the width of the higher hydrogel+500ng group, indicating there was a dose dependent decrease in the defectwidth in response to the hydrogel/inhibitor composite. As seenpreviously, the defect was bridged early in the empty defects as nochanges were seen between 5 and 14 days post-op. PEG-N3+500 ngrmGremlin1 delivered to the polymer hydrogel did not have any impact onbone healing, as there were no differences at either time point betweenthis group and the empty defect. There were no differences among any ofthe groups on post-operative day 5 in the defect thickness, defectmineral content, and defect bone volume, as this time point is beforethe defect undergoes the mineralization that is part of the normaldefect healing, as shown in FIGS. 8 B-D. For both the defect mineralcontent and bone volume there was a dose dependent decrease on post-opday 14; while there was no difference among the empty, hydrogel+carrier,and PEG-N3+500 ng groups, as shown in FIGS. 8 C-D. Additionally, therewere no changes in any of the parameters between days 5 and 14 for thehydrogel+500 ng group indicating that there was no significant bonegrowth observed with these defects.

The results clearly demonstrate that the polymer hydrogel allows forrapid in situ polymerization for controlled delivery of therapeuticproteins. Polymerization of PEG-N3 and DBCO-PEG to form hydrogelsresulted in very rapid crosslinking that occurs spontaneously withoutthe need for any additional initiators. The polymerization for allapplications resulted in a fully cross-linked polymer hydrogel in lessthan 90 seconds. This rapid spontaneous polymerization has the potentialto deliver incorporated factors to any site that can be reachable with aneedle. Furthermore, incorporated proteins retained their biologicalactivity both in vitro and in vivo.

This appears to be the first time Gremlin has been delivered to delaythe rapid bone growth seen in pediatric patients. Not only does thishave tremendous potential to delay the post-operative re-synostosisfrequently seen in cases of craniosynostosis, but it also has thepotential to dramatically change the surgical management of thisdisease. This therapy could allow for the endoscopic removal of thefused suture and in effect re-create the function of a normal suture.This minimally invasive procedure has been abandoned as the results fromthe surgery were temporary. Outside of craniofacial reconstruction,delaying the rate of bone growth has direct applications in treatingfractures of the growth plate and heterotopic ossification. In additionto delivering BMP inhibitors, the plug and play architecture of thePEG-N3 RAFT polymerization also allows the polymer hydrogel to be usedfor other regenerative applications that may necessitate cell adhesionpeptides, cleavable linkages, or covalent attachment of therapeuticsmall molecules.

In Vitro Hydrogel Testing

All in vitro experiments were performed under aseptic conditions.Aqueous stock solutions of DBCO-PEG (12.5%, 6.25%, 4.85%, 3.13%, 1.56%;w:v) and PEG-N3 (50%; w:v) were prepared by sonicating the polymers inPBS at room temperature. Two parts DBCO-PEG and 1 part PEG-N3 wereincubated on ice until mixing by pipetting and injected in to a modifiedsyringe mold. The gels were then incubated at 37° C. in 1 mL of PBS with10% FBS until testing. Unconstrained compression testing was performedwith the samples immersed in PBS, a 0.1±0.01 N preload, a displacementof 3 mm, and a 2 mm/s compression velocity (Bose EnduraTEC 3100, BoseCorporation, Eden Prairie, Minn.). GST was fluorescently labeled withAlexa Fluor 647 carboxylic acid, succinimidyl ester using themanufacturer's protocol, purified with a PD 10 column, lyophilizedovernight, and re-suspended in sterile PBS. Aliquots were diluted 1:5 insterile PBS and quantified by fluorometry. The biological activity ofrmGremlin1 (R&D Systems, Minneapolis, Minn.) delivered from the 12.5%w:v hydrogel was performed by incubating gels containing 150 ngrmGremlin1 or 4 nm HCl vehicle at 37° C. for 7 days in DMEM. Serum and100 ng/mL rhBMP2 (R&D Systems) or vehicle was added to conditionedmedium when MG63 cells were at 80% confluence. After 24 hours cellsalkaline phosphatase activity was measured as previously described ²⁰.

Defect Creation

All procedures were approved by the Georgia Tech Institutional AnimalCare and Use Committee in accordance with the guide for the Care and Useof Laboratory Animals. All calvarial defects were created in post-natalday 21 old male C57B1/6J mice. This is the age at which the mice areweaned and that the PF suture has fused with osteoid but the tissue hasnot yet undergone mineralization to any great extent ¹⁴. Under 28×magnification a 1.5 mm by 2.5 mm defect was made removing the PF sutureusing a piezoelectric instrument under constant irrigation with sterilePBS as previously described. As appropriate the defects were left emptyor injected with 2 μL of the 12.5% hydrogel with the appropriateconcentration of rmGremlin1 or GST-647. The ratios and mixing wereperformed as described above and the polymerization was verified after20 seconds with a blunt 25G needle. All mice were randomized to both thetreatment group and post-operative time point (N=5 per group) with allanalysis conducted by a blinded reviewer. Fluorescence release from micecontaining either the hydrogel+GST-647 or PEG-N3+GST-647 wereanesthetized and imaged on post-operative days 0, 2, 5, and 14 (IVISLumina II) (2 groups n=5). Total fluorescent counts over the entire headand in a 1.5 mm by 2.5 mm were determined using the same display scales.

The effect of rmGremlin1 delivered from the hydrogel was assessed bycreating the cranial defects described above and randomized to contain 2uL of: empty defect, hydrogel only, hydrogel+300 ng rmGremlin1,hydrogel+500 ng rmGremlin1, and the un-polymerized PEG-N3+500 ngrmGremlin1 (5 groups, n=10). On post-op days 5 and 14, mice wereeuthanized and imaged with μCT with a voxel size of 31 um (VivaCT 40,Scanco Medical, Basset, Switzerland). The extent of bone regeneration inthe defect was assessed using an advanced segmentation algorithmdescribed and validated previously^(9,21). Histological assessment wasperformed using haematoxylin and eosin stained 7 □m axial sections.

Demonstration of Polymerization in Defect Control Tests.

The polymer hydrogel has been tested in a mouse calvarial defect. A 1.5mm by 2.5 mm defect was created to remove the posterior frontal suturein juvenile mice. Prior work by the inventors has shown that this defectheals within the first week following surgery. The mice from the studywere randomized to either contain an empty defect or have the polymerhydrogel injected in the defect. The polymer hydrogel did not containany bioactive molecules. There were no complications in injecting thepolymer hydrogel directly onto exposed dura and there were nopostoperative complications. The mice were scanned with micro-computedtomography 5 and 10 days following surgery and processed with apreviously developed algorithm. The algorithm is a modification to thesnake algorithm and has been validated to be within 1% of the serialhistology measurements. The algorithm measured the distance between thebones, the percentage of the defect open, the area of bone in thedefect, the volume of bone in the defect, and the mass of bone in thedefect. There were no significant changes in any of the measurements ateither time point. This suggests that the injecting the polymer hydrogelto polymerize in-situ does not negatively impair bone healing or have asignificant effect on the surrounding tissues. In addition, MRI scans ofthe mice have showed that the polymer hydrogel remains in the defect andthe polymerization does not disrupt the underlying dura.

Statistical Analysis

All data are represented as the mean±standard error of the mean. Thesample size for all in vivo and in vitro experiments was determined by aprospective power analysis based on previously reported data. All cellculture experiments were performed with six independent cultures (n=6)and repeated two times. All in vivo experiments were performed in 5 miceper group per time point (n=5). The normality of the data was verifiedby the D'Agistino-Pearson omnibus normality test. For all in vitroexperiments a one way ANOVA was performed and where appropriatesignificance among groups was determined by a multiple comparison testwith Bonferroni adjustments. For all in vivo experiments a two way ANOVAwas performed and as expected there was a significant (P<0.001) effectof treatment group, time, and interaction for all analyses. Sinceinteractions were found significant, main effect significance was testedby either a conditional one way ANOVA with Bonferroni multiplecomparison post-test or an un-paired two-sided t-test not assuming equalvariance. Statistical significance for all experiments was declared whenthe p-value was less than 0.05.

The following publications in their entireties are hereby incorporatedby reference into this application as if fully set forth herein in orderto more fully describe the state of the art to which the disclosedmatter pertains.

-   Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click Chemistry: Diverse    Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl    40, 2004-2021 (2001).-   Hein, J. E. & Fokin, V. V. Copper-catalyzed azide-alkyne    cycloaddition (CuAAC) and beyond: new reactivity of copper(I)    acetylides. Chem Soc Rev 39, 1302-1315 (2010).-   DeForest, C. A., Polizzotti, B. D. & Anseth, K. S. Sequential click    reactions for synthesizing and patterning three-dimensional cell    microenvironments. Nat Mater 8, 659-664 (2009).-   Ning, X., Guo, J., Wolfert, M. A. & Boons, G. J. Visualizing    metabolically labeled glycoconjugates of living cells by copper-free    and fast huisgen cycloadditions. Angew Chem Int Ed Engl 47,    2253-2255 (2008).-   Hermann, C. et al. Rapid Re-synostosis Following Suturectomy in    Pediatric Mice is Age and Location Dependent. Bone Submitted (2012).-   Hermann, C. D. et al. Biphasic Fusion of the Murine Posterior    Frontal Suture Part 1: Complete Time Course. Plast Reconstr Surg    Submitted (2012).-   Walsh, D. W., Godson, C., Brazil, D. P. & Martin, F. Extracellular    BMP-antagonist regulation in development and disease: tied up in    knots. Trends Cell Biol 20, 244-256 (2010).-   Lee, S. Y. et al. Unconfined compression properties of a porous    poly(vinyl alcohol)-chitosan-based hydrogel after hydration. Acta    Biomater 5, 1919-1925 (2009).-   Khokha, M. K., Hsu, D., Brunet, L. J., Dionne, M. S. &    Harland, R. M. Gremlin is the BMP antagonist required for    maintenance of Shh and Fgf signals during limb patterning. Nat    Genet. 34, 303-307 (2003).-   Topol, L. Z. et al. Biosynthesis, post-translation modification, and    functional characterization of Drm/Gremlin J Biol Chem 275,    8785-8793 (2000).-   Hsu, D. R., Economides, A. N., Wang, X., Eimon, P. M. &    Harland, R. M. The Xenopus dorsalizing factor Gremlin identifies a    novel family of secreted proteins that antagonize BMP activities.    Mol Cell 1, 673-683 (1998).-   Bergmeyer, H. U., Bergmeyer, J. & Grassl, M. Methods of enzymatic    analysis. 3rd edn, (Verlag Chemie, 1983).-   Hermann, C. D. et al. Algorithm to Assess Cranial Suture Fusion with    Varying and Discontinuous Mineral Density Annals of Biomedical    Engineering In Press (2012).-   Cooper, G. M. et al. Noggin inhibits postoperative re-synostosis in    craniosynostotic rabbits. J Bone Miner Res 22, 1046-1054 (2007).-   Cooper, G. M. et al. Ex vivo Noggin gene therapy inhibits bone    formation in a mouse model of postoperative resynostosis. Plast    Reconstr Surg 123, 94S-103S (2009).

The embodiments of the present invention are not limited to theparticular formulations, process steps, and materials disclosed hereinas such formulations, process steps, and materials may vary somewhat.Moreover, the terminology employed herein is used for the purpose ofdescribing exemplary embodiments only and the terminology is notintended to be limiting since the scope of the various embodiments ofthe present invention will be limited only by the appended claims andequivalents thereof.

Therefore, while embodiments of this disclosure have been described indetail with particular reference to exemplary embodiments, those skilledin the art will understand that variations and modifications can beeffected within the scope of the disclosure as defined in the appendedclaims. Accordingly, the scope of the various embodiments of the presentinvention should not be limited to the above-discussed embodiments, andshould only be defined by the following claims and all equivalents.

1. A composition comprising a polymer hydrogel, the polymer hydrogelcomprising: a polyacrylate backbone comprising a structure according toFormula II

wherein R¹ and R² are each independently hydrogen or a C₁ to C₆hydrocarbon; R³ is hydrogen or methyl; X is —O—, —S—, or —NR—; Z is—OR⁶, —SR⁶, or NR⁵R⁶; m is greater than or equal to 1; x is an integergreater than zero and z is zero or an integer greater than zero; R⁵ ishydrogen or C₁ to C₆ hydrocarbon; and R⁶ is hydrogen, C₁ to C₆hydrocarbon or a polyglycol chain of two to ten glycol units; and acrosslinking member comprising a structure according to the Formula III

wherein each R¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′), R^(12′), and R^(13′)is independently hydrogen, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, nitro,fluoro, chloro, or bromo; Y¹ and Y² is each independently —O—, —S—, or—NR⁴—; wherein R⁴ is hydrogen or a C₁ to C₆ hydrocarbon; and L comprisesa polyglycol.
 2. The composition of claim 1, wherein Y¹ is —NH— and Y²is —O—.
 3. The composition of claim 1 wherein L comprises 10-100ethylene glycol units.
 4. The composition of claim 3, wherein L furthercomprises one or more ester, amide, carbonate, carbamate, or ureagroups, or a mixture thereof.
 5. The composition of claim 1 wherein R¹⁰,R¹¹, R¹², R¹³, R^(10′), R^(11′), R^(12′), and R^(13′) are eachindependently hydrogen or fluoride 6.-7. (canceled)
 8. The compositionof claim 1, wherein when z is greater than zero, the ratio of x to z isbetween about 5:1 to about 2:1. 9.-10. (canceled)
 11. The composition ofclaim 1, wherein m is from 2 to about
 6. 12. The composition of claim 1,wherein the polyacrylate backbone and the crosslinking member areconnected through the triazole ring.
 13. The composition of claim 1,wherein the polymer hydrogel has a structure of Formula IX:

wherein R¹ and R² are each independently hydrogen or a C₁ to C₆hydrocarbon; x is an integer greater than zero, z is zero or an integergreater than zero; X is —O— or —NR⁵—; Y¹ is —NH— and Y² is —O—; Z is—OR⁶ or NHR⁶, wherein R⁶ is hydrogen, C₁ to C₆ hydrocarbon or apolyethylene glycol chain of two to ten ethylene glycol units; m isgreater than or equal to 2, and L comprises a polyethylene glycol.14.-15. (canceled)
 16. The composition of claim 1 further comprising atherapeutic agent not chemically bonded to the polymer hydrogel. 17.-19.(canceled)
 20. The composition of claim 16, wherein the therapeuticagent is a protein of between about 15 and about 35 kDa. 21.-22.(canceled)
 22. The composition of claim 16, wherein the therapeuticagent is a recombinant protein that inhibits BMP.
 24. (canceled)
 25. Thecomposition of claim 1, wherein the polymer hydrogel is at aconcentration of about 1.5% to about 15% weight to volume of water. 26.A kit for a therapeutic treatment of an anatomical part of a bodycomprising: an aqueous solution of a polyacrylate azide, an aqueoussolution of a crosslinking alkyne, and an aqueous solution of atherapeutic agent, wherein the polyacrylate azide has a structure ofFormula IV

wherein R¹ and R² are each independently hydrogen or a C₁ to C₆hydrocarbon; R³ is hydrogen or methyl; X is —O— or —NR⁵—; Z is —OR⁶ orNR⁵R⁶; m is greater than or equal to 1; x is an integer greater thanzero and z is zero or an integer greater than zero; R⁵ is hydrogen or C₁to C₆ hydrocarbon; R⁶ is hydrogen, C₁ to C₆ hydrocarbon or apolyethylene glycol chain of two to ten ethylene glycol units; and thecrosslinking alkyne has a structure of formula V

wherein each R¹⁰, R¹¹, R¹², R¹³, R^(10′), R^(11′), R^(12′), and R^(13′)is independently hydrogen, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, nitro,fluoro, chloro, or bromo; Y¹ and Y² is each independently —O—, —S—, or—NR⁴—; wherein R⁴ is hydrogen or a C₁ to C₆ hydrocarbon; and L comprisesa polyglycol.
 27. The kit of claim 26, wherein the anatomical part ofthe body is a bone and the therapeutic agent acts to inhibit oraccelerate bone growth.
 28. The kit of claim 26, wherein the anatomicalpart of the body is a bone and the therapeutic agent inhibits bonegrowth.
 29. The kit of claim 26, wherein the anatomical part of the bodyis a bone and the therapeutic agent inhibits a member of the BMP proteinfamily.
 30. The kit of claim 29, wherein the therapeutic agent is anatural or recombinant protein selected from the group consisting ofGremlin, Noggin, and Sclerostin.
 31. The kit of claim 26, wherein thecrosslinking alkyne has a structure of formula XI


32. The kit of claim 26, wherein the crosslinking alkyne has a structureof formula XII

wherein o is an integer between 10 and
 100. 33. The kit of claim 26,wherein the polyacrylate azide has a structure of formula X

wherein R¹ and R² are each independently hydrogen or methyl, m is aninteger between 2 and 10, and n is an integer between 2 and
 10. 34. Amethod for treating a bone condition, comprising administering to a siteon or near a bone a therapeutic agent in a polymer hydrogel, wherein thepolymeric hydrogel comprises a compound of Formula VI

wherein R¹ and R² are each independently hydrogen or a C₁ to C₆hydrocarbon, R³ is hydrogen or methyl; X is —O— or NR⁵—; Z is —OR⁶ orNR⁵R⁶; m is greater than or equal to 1; x is an integer greater thanzero and z is zero or an integer greater than zero; R⁵ is hydrogen or C₁to C₆ hydrocarbon; R⁶ is hydrogen, C₁ to C₆ hydrocarbon or apolyethylene glycol chain of two to ten ethylene glycol units; Y¹ and Y²is each independently —O— or —NR⁴—; R⁴ is hydrogen or a C₁ to C₆hydrocarbon; and L comprises a polyethylene glycol.
 35. The method ofclaim 34, wherein the therapeutic agent is not chemically bonded to thepolymer hydrogel.
 36. The method of claim 34, wherein the therapeuticagent is a protein or nucleic acid.
 37. The method of claim 34, whereinthe therapeutic agent is a protein of between about 10 to about 50 kDa.38. The method of claim 34, wherein the therapeutic agent is a proteinof between about 15 to about 35 kDa.
 39. The method of claim 34, whereinthe therapeutic agent is a BMP agonist, antagonist, inhibitor oractivator.
 40. The method of claim 34, wherein the biological agent is aBMP inhibitor
 41. The method of claim 34, wherein the biological agentis a recombinant protein that inhibits BMP.
 42. The method of claim 34,wherein the treatment includes the steps of preparing an aqueoussolution of the therapeutic agent; preparing an aqueous solution of apolyacrylate azide of Formula IV

preparing an aqueous solution of a crosslinking alkyne of Formula V

and either combining the three solutions and administering the combinedsolution to the site, or administering the solution of the therapeuticagent followed by a combined solution of the polyacrylate azide and thecrosslinking alkyne to produce the polymer hydrogel.